{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:07:17Z","timestamp":1791446837261,"version":"4.3.3"},"reference-count":31,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T00:00:00Z","timestamp":1711152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jchf.2024.03.006","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T19:11:47Z","timestamp":1714590707000},"page":"1226-1237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cost-Effectiveness of Medical Therapy for Heart\u00a0Failure With Mildly Reduced and Preserved Ejection Fraction"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1517-5682","authenticated-orcid":false,"given":"Neal M.","family":"Dixit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie P.","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9787-3649","authenticated-orcid":false,"given":"Boback","family":"Ziaeian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3192-8093","authenticated-orcid":false,"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2024.03.006_bib1","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1161\/CIRCRESAHA.119.313572","article-title":"Heart failure with preserved ejection fraction in perspective","volume":"124","author":"Pfeffer","year":"2019","journal-title":"Circ Res"},{"issue":"17","key":"10.1016\/j.jchf.2024.03.006_bib2","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2024.03.006_bib3","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jamainternmed.2022.5010","article-title":"Cost-effectiveness of empagliflozin in patients with heart failure with preserved ejection fraction","volume":"182","author":"Zheng","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1016\/j.jchf.2024.03.006_bib4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jamacardio.2023.0077","article-title":"Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors for the treatment of heart failure with preserved ejection fraction","volume":"8","author":"Cohen","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2024.03.006_bib5","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1001\/jamacardio.2023.3216","article-title":"Health and economic evaluation of sacubitril-valsartan for heart failure management","volume":"8","author":"Bhatt","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2024.03.006_bib6","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.03.006_bib7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart\u00a0Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.03.006_bib8","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT \u2014 new insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"31","key":"10.1016\/j.jchf.2024.03.006_bib9","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/eurheartj\/ehad344","article-title":"Sacubitril\/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF","volume":"44","author":"Vaduganathan","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2024.03.006_bib10","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1161\/CIRCULATIONAHA.109.909614","article-title":"Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart\u00a0Failure With Preserved Ejection Fraction Study (I-Preserve) trial","volume":"121","author":"Zile","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.03.006_bib11","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes","volume":"70","author":"Shah","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2024.03.006_bib12","series-title":"Social Security Actuarial Life Tables","year":"2022"},{"key":"10.1016\/j.jchf.2024.03.006_bib13","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.03.006_bib14","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jacc.2019.05.052","article-title":"Age-related characteristics and outcomes of patients with heart failure with preserved ejection fraction","volume":"74","author":"Tromp","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2024.03.006_bib15","first-page":"571","article-title":"Expenditure on heart failure in the United States: The Medical Expenditure Panel Survey 2009-2018","volume":"10","author":"Bhatnagar","year":"2022","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2024.03.006_bib17","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1001\/jamacardio.2021.1437","article-title":"Cost-effectiveness of dapagliflozin for treatment of patients with heart failure with reduced ejection fraction","volume":"6","author":"Parizo","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2024.03.006_bib18","doi-asserted-by":"crossref","first-page":"e2114501","DOI":"10.1001\/jamanetworkopen.2021.14501","article-title":"Cost-effectiveness of dapagliflozin for the treatment of heart failure with reduced ejection fraction","volume":"4","author":"Isaza","year":"2021","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.jchf.2024.03.006_bib19","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.03.006_bib20","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.03.006_bib21","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12955-020-01508-8","article-title":"Impact of hospitalisation on health-related quality of life in patients with chronic heart failure","volume":"18","author":"Albuquerque de Almeida","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jchf.2024.03.006_bib22","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.03.006_bib24","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.jacc.2014.03.016","article-title":"ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines","volume":"63","author":"Anderson","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2024.03.006_bib25","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.amjcard.2020.02.038","article-title":"Trends in treatment for patients hospitalized with heart failure with preserved ejection fraction before and after Treatment of Preserved Cardiac Function Heart\u00a0Failure With an Aldosterone Antagonist (TOPCAT)","volume":"125","author":"Fudim","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2024.03.006_bib26","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2024.03.006_bib27","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.119.044491","article-title":"Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF","volume":"141","author":"McMurray","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.03.006_bib28","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824","article-title":"Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-Preserved Trial","volume":"144","author":"Packer","year":"2021","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.jchf.2024.03.006_bib29","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.03.006_bib30","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.03.006_bib31","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.03.006_bib32","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.03.006_bib33","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177924002579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177924002579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T02:20:54Z","timestamp":1726798854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177924002579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2213177924002579"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2024.03.006","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Medical Therapy for Heart\u00a0Failure With Mildly Reduced and Preserved Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2024.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}